PMID- 23009575
OWN - NLM
STAT- MEDLINE
DCOM- 20130606
LR  - 20211021
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 12
DP  - 2012 Sep 25
TI  - MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated 
      with interferon beta along two-year follow-up.
PG  - 107
LID - 10.1186/1471-2377-12-107 [doi]
AB  - BACKGROUND: In previous studies we found that MHC2TA +1614 genotype frequency was 
      very different when MS patients with and without human herpesvirus 6 (HHV-6) in 
      serum samples were compared; a different clinical behavior was also described. 
      The purpose of the study was: 1. To evaluate if MHC2TA expression in MS patients 
      was influenced by interferon beta (IFN-beta) treatment. 2. To study MHC2TA 
      expression in MS patients with and without minor allele C. 3. To analyze the 
      relation between MHC2TA mRNA levels and HHV-6 active infection in MS patients. 
      METHODS: Blood and serum samples of 154 MS patients were collected in five 
      programmed visits: basal (prior to beginning IFN-beta treatment), six, twelve, 
      eighteen and twenty-four months later. HHV-6 in serum and MHC2TA mRNA levels were 
      evaluated by PCR and RT-PCR, respectively. Neutralizing antibodies (NAbs) against 
      IFN-beta were analyzed by the cytopathic effect assay. RESULTS: We found that 
      MHC2TA mRNA levels were significantly lower among MS patients with HHV-6 active 
      infection at the basal visit (without treatment) than in those MS patients 
      without HHV-6 active infection at the basal visit (p = 0.012); in all the 
      positive samples we only found variant A. Furthermore, 58/99 (58.6%) MS patients 
      without HHV-6 along the five programmed visits and an increase of MHC2TA 
      expression after two-years of IFN-beta treatment were clinical responders vs. 
      5/21 (23.8%) among those MS patients with HHV-6 and a decrease of MHC2TA mRNA 
      levels along the two-years with IFN-beta treatment (p = 0.004); no differences 
      were found between patients with and without NAbs. CONCLUSIONS: MHC2TA mRNA 
      levels could be decreased by the active replication of HHV-6; the absence of 
      HHV-6 in serum and the increase of MHC2TA expression could be further studied as 
      markers of good clinical response to IFN-beta treatment.
FAU - Dominguez-Mozo, Maria Inmaculada
AU  - Dominguez-Mozo MI
AD  - Servicio de Neurologia, Hospital Clinico San Carlos, Instituto de Investigacion 
      Sanitaria del Hospital Clinico San Carlos IdISSC, Madrid, Spain.
FAU - Garcia-Montojo, Marta
AU  - Garcia-Montojo M
FAU - De Las Heras, Virginia
AU  - De Las Heras V
FAU - Garcia-Martinez, Angel
AU  - Garcia-Martinez A
FAU - Arias-Leal, Ana Maria
AU  - Arias-Leal AM
FAU - Casanova, Ignacio
AU  - Casanova I
FAU - Arroyo, Rafael
AU  - Arroyo R
FAU - Alvarez-Lafuente, Roberto
AU  - Alvarez-Lafuente R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120925
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Immunologic Factors)
RN  - 0 (MHC class II transactivator protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Trans-Activators)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Adult
MH  - Antibodies, Neutralizing
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Herpesvirus 6, Human/*isolation & purification
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Interferon-beta/immunology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*drug therapy/genetics/virology
MH  - Nuclear Proteins/*genetics
MH  - RNA, Messenger/genetics
MH  - Roseolovirus Infections/*genetics/immunology/virology
MH  - Trans-Activators/*genetics
MH  - Virus Replication/genetics
PMC - PMC3585729
EDAT- 2012/09/27 06:00
MHDA- 2013/06/07 06:00
PMCR- 2012/09/25
CRDT- 2012/09/27 06:00
PHST- 2012/05/24 00:00 [received]
PHST- 2012/09/24 00:00 [accepted]
PHST- 2012/09/27 06:00 [entrez]
PHST- 2012/09/27 06:00 [pubmed]
PHST- 2013/06/07 06:00 [medline]
PHST- 2012/09/25 00:00 [pmc-release]
AID - 1471-2377-12-107 [pii]
AID - 10.1186/1471-2377-12-107 [doi]
PST - epublish
SO  - BMC Neurol. 2012 Sep 25;12:107. doi: 10.1186/1471-2377-12-107.